Search

GSK plc and IDRx, Inc. (IDRx) announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision therapeutics [...]

H. Lundbeck A/S (Lundbeck), a biopharmaceutical company, and Longboard Pharmaceuticals, Inc (Longboard), a clinical-stage biopharmaceutical company, announced an agreement for Lundbeck to acquire Longboard. Under the terms of the agreement, [...]

Merck, known as MSD outside of the United States and Canada, announced the completion of the acquisition of CN201 from Curon Biopharmaceutical (Curon), a novel investigational clinical-stage bispecific antibody for [...]

COSCIENS Biopharma provided an update on the progress of its merger integration with Ceapro, including planned changes to its management team and advancements across its current business. 'With the initial [...]

Titan Pharmaceuticals, Inc. announced that it has entered into a Merger and Contribution and Share Exchange Agreement (the 'Merger Agreement') regarding a business combination with KE Sdn. Bhd. ('KE'). The [...]

Merck, known as MSD outside of the United States and Canada, and Curon Biopharmaceutical (Curon), a privately held biotechnology company, announced that the companies have entered into a definitive agreement [...]

Wedbush identified potential acquisitions that might be a good fit for Biogen (BIIB) by screening the public biotech universe for companies in at least Phase 2 with market caps between [...]

Daiwa says that while no bidder name was disclosed in Friday's report of takeover interest in Legend Biotech (LEGN), the firm believes the company represents an attractive takeover target for [...]

After Biogen (BIIB) announced the acquisition of HI-Bio, whose lead asset felzartamab is a CD38 targeting antibody, RBC Capital said this provides additional support for a CD38-targeting approach for inflammatory [...]

Biogen and Human Immunology Biosciences announced the companies have entered into a definitive agreement under which Biogen has agreed to acquire HI-Bio for $1.15 billion upfront and up to $650 [...]

Novartis BidCo AG, an indirect wholly owned subsidiary of Novartis AG (NVS), announced the result of its voluntary public takeover offer for the shares of MorphoSys AG (MOR), including all [...]

The Management Board and Supervisory Board of MorphoSys (MOR) issued a joint reasoned statement on the voluntary public takeover offer by Novartis BidCo AG, a wholly owned indirect subsidiary of [...]

Merz Therapeutics, a business of Frankfurt-based Merz Group, reported it has entered into an Asset Purchase Agreement to acquire two commercial medicines from NASDAQ-listed Acorda Therapeutics. Merz said the closing [...]

AbbVie (ABBV) and Landos Biopharma (LABP) announced a definitive agreement under which AbbVie will acquire Landos. Landos' lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist with a bimodal [...]

AbbVie (ABBV) and Landos Biopharma (LABP) announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for [...]

Planegg-headquartered, MorphoSys AG has announced the receipt of US antitrust clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the HSR Act) in connection with the proposed acquisition of MorphoSys [...]

Gilead Sciences (GILD) announced the completion of the previously announced transaction to acquire CymaBay Therapeutics (CBAY) for approximately $4.3B in total equity value. 'The addition of CymaBay's investigational lead product [...]

Gilead Sciences (GILD) announced the completion of the previously announced transaction to acquire CymaBay Therapeutics (CBAY) for $4.3B in total equity value. As a result of the completion of the [...]

Roche announced that it has entered into a definitive agreement with Lonza, under which Lonza will acquire the Genentech manufacturing facility in Vacaville, California, USA, for USD 1.2 billion in [...]

AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). The acquisition marks a major step forward in AstraZeneca delivering [...]

AstraZeneca announced the successful completion of the acquisition of Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune diseases, furthering [...]

GSK plc announced that it has completed the acquisition of Aiolos Bio (Aiolos), a clinical-stage biopharmaceutical company focused on addressing the unmet treatment needs of patients with respiratory and inflammatory [...]

Gilead Sciences, Inc. and CymaBay Therapeutics, Inc. announced a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 [...]

Novartis announced that it has entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG, a Germany-based, global biopharmaceutical company developing innovative medicines in oncology. [...]

Cosette Pharmaceuticals has completed the acquisition of Vyleesi from Palatin Technologies, which includes 5 Orange Book listed patents with protection up to 2041. According to a media release, Palatin and [...]

Eli Lilly and Company announced the successful completion of its acquisition of POINT Biopharma Global Inc., a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development [...]

AstraZeneca has entered into a definitive agreement to acquire Gracell Biotechnologies Inc. (Gracell), a global clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune diseases, [...]

AstraZeneca has entered into a definitive agreement to acquire Icosavax, Inc., a US-based clinical-stage biopharmaceutical company focused on developing differentiated, high-potential vaccines using an innovative, protein virus-like particle (VLP) platform. [...]

Byline: Our Bureau Syngene International has announced the conclusion of the acquisition of a multi-modal biologics manufacturing facility from Stelis Biopharma as announced on 4 July 2023. The acquisition of [...]